Bacteriophage Therapy: Current Strategies and Future Perspectives

Abstract

Antimicrobial resistance represents a significant global health threat, demanding alternative treatments beyond traditional antibiotics. Phage therapy has resurged as a promising solution to address this challenge. This manuscript offers an in-depth examination of phage applications in clinical settings, encompassing the treatment of multidrug-resistant infections, prevention of hospital-acquired infections, and development of phage-based vaccines. Advanced strategies are explored, including phage–antibiotic synergy, biomaterial-enhanced delivery systems to improve phage stability, and the rational design of engineered phages to expand host range and optimize lytic efficacy. Additionally, the application of genetic engineering to broaden phage host ranges and convert temperate phages into lytic variants is discussed. In hospital infection prevention, phages demonstrate substantial potential, such as eliminating bacterial biofilms on medical devices, disinfecting environmental surfaces, and controlling waterborne pathogens in hospital water systems. Furthermore, phages offer a versatile platform for vaccine development, facilitating efficient antigen display and nucleic acid delivery. Despite progress, challenges persist in pharmacokinetics, standardized production, and regulatory approval. This review synthesizes recent preclinical and clinical developments, emphasizing the transformative potential of phage-based therapies while acknowledging the barriers to their clinical implementation.

Keywords

antimicrobial resistance / hospital-acquired infections / phage–antibiotic synergy / phage-based vaccines / phage therapy

References

[1] R. A. Gladstone, A. McNally, A. K. Pöntinen, et al., “Emergence and Dissemination of Antimicrobial Resistance in Escherichia Coli Causing Bloodstream Infections in Norway in 2002–17: A Nationwide, Longitudinal, Microbial Population Genomic Study,” The Lancet Microbe 2, no. 7 (2021): e331.

[2] M. E. Carey, Z. A. Dyson, D. J. Ingle, et al., “Global Diversity and Antimicrobial Resistance of Typhoid Fever Pathogens: Insights From a Meta-Analysis of 13,000 Salmonella Typhi Genomes,” Elife 12 (2023): e85867.

[3] I. N. Okeke, M. E. A. de Kraker, T. P. Van Boeckel, et al., “The Scope of the Antimicrobial Resistance Challenge,” Lancet 403, no. 10442 (2024): 2426–2438.

[4] Antimicrobial Resistance, Collaborators. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. Lancet 2022; 399(10325): 629–655.

[5] R. Laxminarayan, P. Matsoso, S. Pant, et al., “Access to Effective Antimicrobials: A Worldwide Challenge,” Lancet 387, no. 10014 (2016): 168–175.

[6] V. H. Krishnaprasad, V. Nayak, and S. Kumar, “World Health Organisation's Bacterial Pathogen Priority List (Bppl) 2017 and Bppl 2024 to Combat Global Antimicrobial Resistance Crisis: ‘Challenges and Opportunities’,” The Journal of Antimicrobial Chemotherapy 80, no. 8 (2025): 2061–2069.

[7] L. Chen, S. Kumar, and H. Wu, “A Review of Current Antibiotic Resistance and Promising Antibiotics With Novel Modes of Action to Combat Antibiotic Resistance,” Archives of Microbiology 205, no. 11 (2023): 356.

[8] H. Sati, E. Carrara, A. Savoldi, et al., “The Who Bacterial Priority Pathogens List 2024: A Prioritisation Study to Guide Research, Development, and Public Health Strategies Against Antimicrobial Resistance,” The Lancet Infectious Diseases (2025). S1473-3099(25)00118-5 [pii].

[9] B. Blasco, S. Jang, H. Terauchi, et al., “High-Throughput Screening of Small-Molecules Libraries Identified Antibacterials Against Clinically Relevant Multidrug-Resistant A.?Baumannii and K.?Pneumoniae,” EBioMedicine 102 (2024): 105073.

[10] M. S. Butler, I. R. Henderson, R. J. Capon, and M. A. T. Blaskovich, “Antibiotics in the Clinical Pipeline as of December 2022,” The Journal of Antibiotics 76, no. 8 (2023): 431–473.

[11] J. Madden and K. Outterson, “Trends in the Global Antibiotics Market,” Nature Reviews Drug Discovery 22, no. 3 (2023): 174.

[12] K. Moon, C. Coxon, C. Ardal, et al., “Considerations and Perspectives on Phage Therapy From the Transatlantic Taskforce on Antimicrobial Resistance,” Nature Communications 16, no. 1 (2025): 10883.

[13] S. A. Strathdee, G. F. Hatfull, V. K. Mutalik, and R. T. Schooley, “Phage Therapy: From Biological Mechanisms to Future Directions,” Cell 186, no. 1 (2023): 17–31.

[14] H. W. Ackermann, “Phage Classification and Characterization,” Methods in Molecular Biology (Clifton, NJ) 501 (2009): 127–140.

[15] G. Ofir and R. Sorek, “Contemporary Phage Biology: From Classic Models to New Insights,” Cell 172, no. 6 (2018): 1260–1270.

[16] E. Adriaenssens and J. R. Brister, “How to Name and Classify Your Phage: An Informal Guide,” Viruses 9, no. 4 (2017): 70.

[17] F. L. Nobrega, M. Vlot, P. A. de Jonge, et al., “Targeting Mechanisms of Tailed Bacteriophages,” Nature Reviews Microbiology 16, no. 12 (2018): 760–773.

[18] D. Kirk, R. Costeira, A. Visconti, et al., “Bacteriophages, Gut Bacteria, and Microbial Pathways Interplay in Cardiometabolic Health,” Cell Reports 43, no. 2 (2024): 113728.

[19] S. R. Grigson, S. K. Giles, R. A. Edwards, and B. Papudeshi, “Knowing and Naming: Phage Annotation and Nomenclature for Phage Therapy,” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 77, no. Suppl 5 (2023): S352–S359.

[20] K. Dabrowska, “Phage Therapy: What Factors Shape Phage Pharmacokinetics and Bioavailability? Systematic and Critical Review,” Medicinal Research Reviews 39, no. 5 (2019): 2000–2025.

[21] M. Siopi, D. Skliros, P. Paranos, et al., “Pharmacokinetics and Pharmacodynamics of Bacteriophage Therapy: A Review With a Focus on Multidrug-Resistant Gram-Negative Bacterial Infections,” Clinical Microbiology Reviews 37, no. 3 (2024): e0004424.

[22] P. Kim, A. M. Sanchez, T. J. R. Penke, et al., “Safety, Pharmacokinetics, and Pharmacodynamics of Lbp-Ec01, a Crispr-Cas3-Enhanced Bacteriophage Cocktail, in Uncomplicated Urinary Tract Infections due to Escherichia Coli (Eliminate): The Randomised, Open-Label, First Part of a Two-Part Phase 2 Trial,” The Lancet Infectious Diseases 24, no. 12 (2024): 1319–1332.

[23] M. Skurnik, S. Alkalay-Oren, M. Boon, et al., “Phage Therapy,” Nature Reviews Methods Primers 5, no. 1 (2025): 9.

[24] E. A. Ashworth, R. C. T. Wright, R. K. Shears, et al., “Exploiting Lung Adaptation and Phage Steering to Clear Pan-Resistant Pseudomonas Aeruginosa Infections in Vivo,” Nature Communications 15, no. 1 (2024): 1547.

[25] D. Fang, L. Jin, Q. Song, et al., “Pharmacokinetic Study of Vibrio Parahaemolyticus Phage Фvp140 in Litopenaeus Vannamei Following Oral Administration,” Aquaculture 606 (2025): 742619.

[26] Q. Chunye, Y. Huijing, W. Xiaojie, and Z. Jing, “Clinical Development Advances and Challenges for Novel Non-Traditional Narrow Spectrum Antibiotics,” Chinese Journal of Antibiotics 50, no. 10 (2025): 1123–1134.

[27] H. Yin, W. Yi, J. Wu, K. Wang, and J. Guan, “Adaptive Fuzzy Neural Network Pid Algorithm for Bldcm Speed Control System,” Mathematics 10, no. 1 (2022): 118.

[28] H. S. Choi, W. Liu, P. Misra, et al., “Renal Clearance of Quantum Dots,” Nature Biotechnology 25, no. 10 (2007): 1165–1170.

[29] M. C. Bichet, W. H. Chin, W. Richards, et al., “Bacteriophage Uptake by Mammalian Cell Layers Represents a Potential Sink That May Impact Phage Therapy,” Iscience 24, no. 4 (2021): 102287.

[30] B. R. Tiwari, S. Kim, M. Rahman, and J. Kim, “Antibacterial Efficacy of Lytic Pseudomonas Bacteriophage in Normal and Neutropenic Mice Models,” Journal of Microbiology (Seoul, Korea) 49, no. 6 (2011): 994–999.

[31] M. Popescu, J. D. Van Belleghem, A. Khosravi, and P. L. Bollyky, “Bacteriophages and the Immune System,” Annual Review of Virology 8, no. 1 (2021): 415–435.

[32] K. Gembara and K. Dabrowska, “Phage-Specific Antibodies,” Current Opinion in Biotechnology 68 (2021): 186–192.

[33] Z. Kazmierczak, J. Majewska, P. Miernikiewicz, et al., “Immune Response to Therapeutic Staphylococcal Bacteriophages in Mammals: Kinetics of Induction, Immunogenic Structural Proteins, Natural and Induced Antibodies,” Frontiers in Immunology 12 (2021): 639570.

[34] M. Zaczek, M. Lusiak-Szelachowska, E. Jonczyk-Matysiak, et al., “Antibody Production in Response to Staphylococcal Ms-1 Phage Cocktail in Patients Undergoing Phage Therapy,” Frontiers in Microbiology 7 (2016): 1681.

[35] M. Lusiak-Szelachowska, R. Miedzybrodzki, P. Rogoz, B. Weber-Dabrowska, M. Zaczek, and A. Gorski, “Do Anti-Phage Antibodies Persist After Phage Therapy? A Preliminary Report,” Antibiotics (Basel) 11, no. 10 (2022): 1358.

[36] R. M. Dedrick, K. G. Freeman, J. A. Nguyen, et al., “Potent Antibody-Mediated Neutralization Limits Bacteriophage Treatment of a Pulmonary Mycobacterium Abscessus Infection,” Nature Medicine 27, no. 8 (2021): 1357–1361.

[37] G. A. Suh, T. P. Lodise, P. D. Tamma, et al., “Considerations for the Use of Phage Therapy in Clinical Practice,” Antimicrobial Agents and Chemotherapy 66, no. 3 (2022): e0207121.

[38] Y. Mulla, J. Muller, D. Trimcev, and T. Bollenbach, “Extreme Diversity of Phage Amplification Rates and Phage-Antibiotic Interactions Revealed by Phorce,” Plos Biology 23, no. 4 (2025): e3003065.

[39] S. C. Nang, Y. W. Lin, A. Petrovic Fabijan, et al., “Pharmacokinetics/Pharmacodynamics of Phage Therapy: A Major Hurdle to Clinical Translation,” Clinical Microbiology and Infection 29, no. 6 (2023): 702–709.

[40] B. J. Cairns, A. R. Timms, V. A. Jansen, I. F. Connerton, and R. J. Payne, “Quantitative Models of in Vitro Bacteriophage-Host Dynamics and Their Application to Phage Therapy,” Plos Pathogens 5, no. 1 (2009): e1000253.

[41] K. Dabrowska and S. T. Abedon, “Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies,” Microbiology and Molecular Biology Reviews 83, no. 4 (2019): e00012–19.

[42] J. P. Pirnay, S. Djebara, G. Steurs, et al., “Personalized Bacteriophage Therapy Outcomes for 100 Consecutive Cases: A Multicentre, Multinational, Retrospective Observational Study,” Nature Microbiology 9, no. 6 (2024): 1434–1453.

[43] K. Champagne-Jorgensen, T. Luong, T. Darby, and D. R. Roach, “Immunogenicity of Bacteriophages,” Trends in Microbiology 31, no. 10 (2023): 1058–1071.

[44] K. Bosco, S. Lynch, I. Sandaradura, and A. Khatami, “Therapeutic Phage Monitoring: A Review,” Clinical Infectious Diseases 77, no. Suppl 5 (2023): S384–S394.

[45] M. K. Kim, G. A. Suh, G. D. Cullen, et al., “Bacteriophage Therapy for Multidrug-Resistant Infections: Current Technologies and Therapeutic Approaches,” Journal of Clinical Investigation 135, no. 5 (2025): e187996.

[46] A. Jedrusiak, W. Fortuna, J. Majewska, A. Gorski, and E. Jonczyk-Matysiak, “Phage Interactions With the Nervous System in Health and Disease,” Cells 12, no. 13 (2023): 1720.

[47] C. Ghose, M. Ly, L. K. Schwanemann, et al., “The Virome of Cerebrospinal Fluid: Viruses Where We Once Thought There Were None,” Frontiers in Microbiology 10 (2019): 2061.

[48] A. Khatami, D. A. Foley, M. S. Warner, et al., “Standardised Treatment and Monitoring Protocol to Assess Safety and Tolerability of Bacteriophage Therapy for Adult and Paediatric Patients (Stamp Study): Protocol for an Open-Label, Single-Arm Trial,” BMJ Open 12, no. 12 (2022): e065401.

[49] M. Zhao, H. Li, D. Gan, M. Wang, H. Deng, and Q. E. Yang, “Antibacterial Effect of Phage Cocktails and Phage-Antibiotic Synergy Against Pathogenic Klebsiella Pneumoniae,” mSystems 9, no. 9 (2024): e0060724.

[50] M. Koncz, T. Stirling, H. Hadj Mehdi, et al., “Genomic Surveillance as a Scalable Framework for Precision Phage Therapy Against Antibiotic-Resistant Pathogens,” Cell 187, no. 21 (2024): 5901–. 18 e28.

[51] F. Molina, M. Menor-Flores, and M. A. Vega-Rodriguez, “Socialviruses: Integrating Quantitative Phage-Bacteria and Phage-Phage Interaction Networks for Rational Cocktail Design,” Bioinformatics Advances 5, no. 1 (2025): vbaf239.

[52] M. P. Nikolich and A. A. Filippov, “Bacteriophage Therapy: Developments and Directions,” Antibiotics (Basel) 9, no. 3 (2020): 135.

[53] F. Cold, N. S. Olsen, A. Djurhuus, and L. H. Hansen, “Bacteriophage Therapy.,” Ugeskrift for Laeger 182, no. 27 (2020): V01200041.

[54] E. K. Tian, Y. Wang, Z. X. Wu, Z. Q. Wan, and W. Cheng, “Bacteriophage Therapy: Retrospective Review and Future Prospects],” Sichuan Da Xue Xue Bao Yi Xue Ban = Journal of Sichuan University Medical Science Edition 52, no. 2 (2021): 170–175.

[55] J. Iredell, H. Sinclair, and A. Khatami, “Personalized Bacteriophage Therapy for Difficult-to-Treat Infections,” Nature Microbiology 9, no. 6 (2024): 1401–1402.

[56] K. C. Benjamin, G. L. Stanley, K. E. Kortright, et al., “Personalized Inhaled Bacteriophage Therapy for Treatment of Multidrug-Resistant Pseudomonas Aeruginosa in Cystic Fibrosis,” Nature Medicine 31, no. 5 (2025): 1494–1501.

[57] S. Wurstle, J. Stender, J. A. Hammerl, et al., “Practical Assessment of an Interdisciplinary Bacteriophage Delivery Pipeline for Personalized Therapy of Gram-Negative Bacterial Infections,” Pharmaceuticals (Basel) 15, no. 2 (2022): 186.

[58] H. Yang, J. Xue, J. Li, et al., “Green Fluorescent Protein-Fused Bacteriophage Cellular Wall-Binding Domain as Broad-Spectrum Signal Probe for Fluorimetry of Methicillin-Resistant Staphylococcus Aureus Strains,” Analytica Chimica Acta 1207 (2022): 339799.

[59] K. K. Kering, B. J. Kibii, and H. Wei, “Biocontrol of Phytobacteria With Bacteriophage Cocktails,” Pest Management Science 75, no. 7 (2019): 1775–1781.

[60] D. Gao, H. Ji, L. Wang, et al., “Fitness Trade-Offs in Phage Cocktail-Resistant Salmonella Enterica Serovar Enteritidis Results in Increased Antibiotic Susceptibility and Reduced Virulence,” Microbiology Spectrum 10, no. 5 (2022): e0291422.

[61] M. Merabishvili, J. P. Pirnay, and D. De Vos, “Guidelines to Compose an Ideal Bacteriophage Cocktail,” Methods in Molecular Biology 2734 (2024): 49–66.

[62] M. Aguilera, E. Tobar-Calfucoy, V. Rojas-Martinez, et al., “Development and Characterization of a Bacteriophage Cocktail With High Lytic Efficacy Against Field-Isolated Salmonella Enterica,” Poultry Science 102, no. 12 (2023): 103125.

[63] L. Huang, W. Guo, J. Lu, W. Pan, F. Song, and P. Wang, “Enterococcus Faecalis Bacteriophage Vb_Efas_Efap05-1 Targets the Surface Polysaccharide and Comea Protein as the Receptors,” Frontiers in Microbiology 13 (2022): 866382.

[64] M. Aguilera, S. Martinez, M. Tello, M. J. Gallardo, and V. Garcia, “Use of Cocktail of Bacteriophage for Salmonella Typhimurium Control in Chicken Meat,” Foods 11, no. 8 (2022): 1164.

[65] B. Hegarty, “Making Waves: Intelligent Phage Cocktail Design, a Pathway to Precise Microbial Control in Water Systems,” Water Research 268, no. Pt A (2025): 122594.

[66] S. Ko, J. Kim, J. H. Cho, Y. Kim, and D. Kim, “Deep Learning-Guided Structural Analysis of a Novel Bacteriophage Kpp105 Against Multidrug-Resistant Klebsiella Pneumoniae,” Computational and Structural Biotechnology Journal 27 (2025): 1827–1837.

[67] X. Zhao, X. Zhong, S. Yang, et al., “Guiding Antibiotics towards Their Target Using Bacteriophage Proteins,” Nature Communications 15, no. 1 (2024): 5287.

[68] J. Gil, J. Paulson, M. Brown, et al., “Tailoring the Host Range of Ackermannviridae Bacteriophages Through Chimeric Tailspike Proteins,” Viruses 15, no. 2 (2023): 286.

[69] K. V. Gorzelnik and J. Zhang, “Cryo-Em Reveals Infection Steps of Single-Stranded Rna Bacteriophages,” Progress in Biophysics and Molecular Biology 160 (2021): 79–86.

[70] R. Meng, M. Jiang, Z. Cui, et al., “Structural Basis for the Adsorption of a Single-Stranded Rna Bacteriophage,” Nature Communications 10, no. 1 (2019): 3130.

[71] B. Kim, S. Y. Lee, J. Park, S. Song, K. P. Kim, and E. Roh, “Bacteriophage Cocktail Comprising Fifi044 and Fifi318 for Biocontrol of Erwinia Amylovora,” Plant Pathology Journal 40, no. 2 (2024): 160–170.

[72] J. Vacheron, C. M. Heiman, D. Garrido-Sanz, M. Caroff, M. Darabi, and C. Keel, “Single Nucleotide Switches Confer Bacteriophage Resistance to Pseudomonas Protegens,” Microlife 6 (2025): uqaf028.

[73] M. K. Kim, Q. Chen, A. Echterhof, et al., “A Blueprint for Broadly Effective Bacteriophage-Antibiotic Cocktails Against Bacterial Infections,” Nature Communications 15, no. 1 (2024): 9987.

[74] H. Duyvejonck, M. Merabishvili, J. P. Pirnay, et al., “Development of a Qpcr Platform for Quantification of the Five Bacteriophages Within Bacteriophage Cocktail 2 (Bfc2),” Scientific Reports 9, no. 1 (2019): 13893.

[75] Y. D. Niu, H. Liu, H. Du, et al., “Efficacy of Individual Bacteriophages Does Not Predict Efficacy of Bacteriophage Cocktails for Control of Escherichia Coli O157,” Frontiers in Microbiology 12 (2021): 616712.

[76] Y. Zhao, M. Ye, X. Zhang, et al., “Comparing Polyvalent Bacteriophage and Bacteriophage Cocktails for Controlling Antibiotic-Resistant Bacteria in Soil-Plant System,” Science of the Total Environment 657 (2019): 918–925.

[77] J. B. Doub, J. Tran, R. Smith, et al., “Feasibility of Using Bacteriophage Therapy to Reduce Morbidity and Mortality Associated With Spinal Epidural Abscesses,” Infection and Chemotherapy 55, no. 2 (2023): 257–263.

[78] M. M. Molendijk, B. Boekema, K. R. Lattwein, et al., “Bacteriophage Therapy Reduces Staphylococcus Aureus in a Porcine and Human Ex Vivo Burn Wound Infection Model,” Antimicrobial Agents and Chemotherapy 68, no. 9 (2024): e0065024.

[79] C. W. Y. Wong and S. Wang, “Efficacy of Repeated Applications of Bacteriophages on Salmonella Enterica-Infected Alfalfa Sprouts during Germination,” Pathogens 11, no. 10 (2022): 1156.

[80] P. Korzeniowski, P. Sliwka, M. Kuczkowski, D. Misic, A. Milcarz, and M. Kuzminska-Bajor, “Bacteriophage Cocktail Can Effectively Control Salmonella Biofilm in Poultry Housing,” Frontiers in Microbiology 13 (2022): 901770.

[81] S. McCallin, J. C. Sacher, J. Zheng, and B. K. Chan, “Current State of Compassionate Phage Therapy,” Viruses 11, no. 4 (2019): 343.

[82] S. Kraus, M. L. Fletcher, U. Apińska, et al., “Phage-Induced Efflux Down-Regulation Boosts Antibiotic Efficacy,” PLoS Pathogens 20, no. 6 (2024): e1012361.

[83] W. N. Chaudhry, J. Concepción-Acevedo, T. Park, S. Andleeb, J. J. Bull, and B. R. Levin, “Synergy and Order Effects of Antibiotics and Phages in Killing Pseudomonas Aeruginosa Biofilms,” PLoS ONE 12, no. 1 (2017): e0168615.

[84] M. E. Stellfox, C. Fernandes, R. K. Shields, et al., “Bacteriophage and Antibiotic Combination Therapy for Recurrent Enterococcus Faecium Bacteremia,” MBio 15, no. 3 (2024): e0339623.

[85] B. K. Chan, P. E. Turner, S. Kim, H. R. Mojibian, J. A. Elefteriades, and D. Narayan, “Phage Treatment of an Aortic Graft Infected With Pseudomonas Aeruginosa,” Evolution, Medicine, and Public Health 2018, no. 1 (2018): 60–66.

[86] A. Eskenazi, C. Lood, J. Wubbolts, et al., “Combination of Pre-Adapted Bacteriophage Therapy and Antibiotics for Treatment of Fracture-Related Infection due to Pandrug-Resistant Klebsiella Pneumoniae,” Nature Communications 13, no. 1 (2022): 302.

[87] B. Van Nieuwenhuyse, D. Van der Linden, O. Chatzis, et al., “Bacteriophage-Antibiotic Combination Therapy Against Extensively Drug-Resistant Pseudomonas Aeruginosa Infection to Allow Liver Transplantation in a Toddler,” Nature Communications 13, no. 1 (2022): 5725.

[88] A. M. Comeau, F. Tétart, S. N. Trojet, M. F. Prère, and H. M. Krisch, “Phage-Antibiotic Synergy (Pas): Beta-Lactam and Quinolone Antibiotics Stimulate Virulent Phage Growth,” PLoS ONE 2, no. 8 (2007): e799.

[89] X. Li, T. Hu, J. Wei, et al., “Characterization of a Novel Bacteriophage Henu2 and Evaluation of the Synergistic Antibacterial Activity of Phage-Antibiotics,” Antibiotics (Basel, Switzerland) 10, no. 2 (2021): 174.

[90] X. Li, Y. He, Z. Wang, et al., “A Combination Therapy of Phages and Antibiotics: Two Is Better than One,” International Journal of Biological Sciences 17, no. 13 (2021): 3573–3582.

[91] J. H. Forsyth, R. Patwa, X. Kostoulias, et al., “Bacteriophage-Resistant Acinetobacter Baumannii Are Resensitized to Antimicrobials,” Nature Microbiology 6, no. 2 (2021): 157–161.

[92] X. Wang, B. Loh, F. Gordillo Altamirano, Y. Yu, X. Hua, and S. Leptihn, “Colistin-Phage Combinations Decrease Antibiotic Resistance in Acinetobacter Baumannii via Changes in Envelope Architecture,” Emerging Microbes & Infections 10, no. 1 (2021): 2205–2219.

[93] K. Qin, X. Shi, K. Yang, et al., “Phage-Antibiotic Synergy Suppresses Resistance Emergence of Klebsiella Pneumoniae by Altering the Evolutionary Fitness,” MBio 15, no. 10 (2024): e0139324.

[94] T. Glonti, N. Chanishvili, and P. W. Taylor, “Bacteriophage-Derived Enzyme That Depolymerizes the Alginic Acid Capsule Associated With Cystic Fibrosis Isolates of Pseudomonas Aeruginosa,” Journal of Applied Microbiology 108, no. 2 (2010): 695–702.

[95] R. A. Hatch and N. L. Schiller, “Alginate Lyase Promotes Diffusion of Aminoglycosides Through the Extracellular Polysaccharide of Mucoid Pseudomonas Aeruginosa,” Antimicrobial Agents and Chemotherapy 42, no. 4 (1998): 974–977.

[96] D. Ma, L. Li, K. Han, et al., “The Antagonistic Interactions Between a Polyvalent Phage Sap7 and Β-Lactam Antibiotics on Combined Therapies,” Veterinary Microbiology 266 (2022): 109332.

[97] S. T. Abedon, “Phage-Antibiotic Combination Treatments: Antagonistic Impacts of Antibiotics on the Pharmacodynamics of Phage Therapy?,” Antibiotics (Basel, Switzerland) 8, no. 4 (2019): 182.

[98] S. Lin, G. Xie, J. He, L. Meng, Y. Pang, and J. Liu, “Enhancing Phage Therapy by Coating Single Bacteriophage-Infected Bacteria With Polymer to Preserve Phage Vitality,” Nature Biomedical Engineering 9, no. 7 (2025): 1155–1171.

[99] Y. Zhao, M. Zhu, Y. Ling, et al., “Correction to “a DNA Nanopatch-Bacteriophage System Targeting Streptococcus Gallolyticus for Inflammatory Bowel Disease Treatment and Colorectal Cancer Prevention”,” Advanced Materials 37, no. 44 (2025): e13718.

[100] B. B. Hsu, I. N. Plant, L. Lyon, F. M. Anastassacos, J. C. Way, and P. A. Silver, “In Situ Reprogramming of Gut Bacteria by Oral Delivery,” Nature Communications 11, no. 1 (2020): 5030.

[101] G. Rahimzadeh, M. Saeedi, M. Moosazadeh, et al., “Encapsulation of Bacteriophage Cocktail Into Chitosan for the Treatment of Bacterial Diarrhea,” Scientific Reports 11, no. 1 (2021): 15603.

[102] X. Dong, P. Pan, D. W. Zheng, P. Bao, X. Zeng, and X. Z. Zhang, “Bioinorganic Hybrid Bacteriophage for Modulation of Intestinal Microbiota to Remodel Tumor-Immune Microenvironment Against Colorectal Cancer,” Science Advances 6, no. 20 (2020): eaba1590.

[103] S. Chhibber, J. Kaur, and S. Kaur, “Liposome Entrapment of Bacteriophages Improves Wound Healing in a Diabetic Mouse Mrsa Infection,” Frontiers in Microbiology 9 (2018): 561.

[104] D. Dehari, A. Chaudhuri, D. N. Kumar, et al., “A Bacteriophage Microgel Effectively Treats the Multidrug-Resistant Acinetobacter Baumannii Bacterial Infections in Burn Wounds,” Pharmaceuticals (Basel) 16, no. 7 (2023): 942.

[105] D. Dehari, A. Chaudhuri, D. N. Kumar, et al., “A Bacteriophage-Loaded Microparticle Laden Topical Gel for the Treatment of Multidrug-Resistant Biofilm-Mediated Burn Wound Infection,” Aaps Pharmscitech [Electronic Resource] 24, no. 6 (2023): 165.

[106] D. Dehari, D. N. Kumar, A. Chaudhuri, et al., “Bacteriophage Entrapped Chitosan Microgel for the Treatment of Biofilm-Mediated Polybacterial Infection in Burn Wounds,” International Journal of Biological Macromolecules 253, no. Pt 5 (2023): 127247.

[107] S. Tao, A. Hu, E. Bavel, et al., “Bio-Responsive Hydrogel for Targeted on-Demand Release of a Phage Cocktail for Treatment of Pseudomonas Aeruginosa Infection,” Advanced Functional Materials 36 (2026): e09360.

[108] J. Park, M. A. Hassan, A. Nabawy, et al., “Engineered Bacteriophage-Polymer Nanoassemblies for Treatment of Wound Biofilm Infections,” ACS Nano 18, no. 39 (2024): 26928–26936.

[109] L. Wang, X. Fan, M. G. Moreno, et al., “Photocatalytic Quantum Dot-Armed Bacteriophage for Combating Drug-Resistant Bacterial Infection,” Advanced Science (Weinheim) 9, no. 17 (2022): e2105668.

[110] B. Ran, Y. Yuan, W. Xia, et al., “A Photo-Sensitizable Phage for Multidrug-Resistant Acinetobacter Baumannii Therapy and Biofilm Ablation,” Chemical Science 12, no. 3 (2020): 1054–1061.

[111] L. Jin, F. Cao, Y. Gao, et al., “Microenvironment-Activated Nanozyme-Armed Bacteriophages Efficiently Combat Bacterial Infection,” Advanced Materials 35, no. 30 (2023): e2301349.

[112] L. Wang, Y. Mai, J. Zhang, et al., “Polyvalent Bacteriophages Conjugated With Ros-Scavenging Nanozymes Enhance Antibiotic-Resistant Biofilm Disruption and Anti-Inflammatory Therapy,” Chemical Engineering Journal 505 (2025): 159666.

[113] J. A. Wroe, C. T. Johnson, and A. J. Garcia, “Bacteriophage Delivering Hydrogels Reduce Biofilm Formation in Vitro and Infection in Vivo,” Journal of Biomedical Materials Research Part A 108, no. 1 (2020): 39–49.

[114] S. Singla, K. Harjai, O. P. Katare, and S. Chhibber, “Bacteriophage-Loaded Nanostructured Lipid Carrier: Improved Pharmacokinetics Mediates Effective Resolution of Klebsiella Pneumoniae-Induced Lobar Pneumonia,” Journal of Infectious Diseases 212, no. 2 (2015): 325–334.

[115] R. Agarwal, C. T. Johnson, B. R. Imhoff, R. M. Donlan, N. A. McCarty, and A. J. Garcia, “Inhaled Bacteriophage-Loaded Polymeric Microparticles Ameliorate Acute Lung Infections,” Nature Biomedical Engineering 2, no. 11 (2018): 841–849.

[116] P. P. Kalelkar, D. A. Moustafa, M. Riddick, J. B. Goldberg, N. A. McCarty, and A. J. Garcia, “Bacteriophage-Loaded Poly(Lactic-Co-Glycolic Acid) Microparticles Mitigate Staphylococcus Aureus Infection and Cocultures of Staphylococcus Aureus and Pseudomonas Aeruginosa,” Advanced Healthcare Materials 11, no. 10 (2022): e2102539.

[117] M. Y. Liu, X. Liu, C. Y. Wang, et al., “Inhalable Polymeric Microparticles for Phage and Photothermal Synergistic Therapy of Methicillin-Resistant Staphylococcus Aureus Pneumonia,” Nano Letters 24, no. 28 (2024): 8752–8762.

[118] S. S. Sawant, M. U. Ahmed, N. G. Gantala, C. Chiu, L. Qu, and Q. Zhou, “Development of Inhalable Bacteriophage Liposomes Against Pseudomonas Aeruginosa,” Pharmaceutics 17, no. 4 (2025): 405.

[119] Y. Cao, Y. Wang, M. Li, D. Khanal, and H. K. Chan, “Can Bacteriophage Be Stabilised by Lipid Encapsulation When Nebulised for Inhalation Delivery Against Pseudomonas Aeruginosa?,” International Journal of Pharmaceutics 678 (2025): 125670.

[120] A. Fulgione, F. Ianniello, M. Papaianni, et al., “Biomimetic Hydroxyapatite Nanocrystals Are an Active Carrier for Salmonella Bacteriophages,” International Journal of Nanomedicine 14 (2019): 2219–2232.

[121] L. Meng, F. Yang, Y. Pang, et al., “Nanocapping-Enabled Charge Reversal Generates Cell-Enterable Endosomal-Escapable Bacteriophages for Intracellular Pathogen Inhibition,” Science Advances 8, no. 28 (2022): eabq2005.

[122] M. Yao, J. Xie, H. Du, D. J. McClements, H. Xiao, and L. Li, “Progress in Microencapsulation of Probiotics: A Review,” Comprehensive Reviews in Food Science and Food Safety 19, no. 2 (2020): 857–874.

[123] V. Chanthavong, N. Vigad, W. Pelyuntha, et al., “Effectiveness of a Single-Dose Phage Cocktail on the Reduction of Multidrug-Resistant Escherichia Coli in Suckling Piglets,” Veterinary Microbiology 302 (2025): 110395.

[124] M. Xu, Y. Hu, Y. Xiao, et al., “Near-Infrared-Controlled Nanoplatform Exploiting Photothermal Promotion of Peroxidase-Like and Oxd-Like Activities for Potent Antibacterial and Anti-Biofilm Therapies,” ACS Applied Materials & Interfaces 12, no. 45 (2020): 50260–50274.

[125] W. Xiu, L. Wan, K. Yang, et al., “Potentiating Hypoxic Microenvironment for Antibiotic Activation by Photodynamic Therapy to Combat Bacterial Biofilm Infections,” Nature Communications 13, no. 1 (2022): 3875.

[126] H. Ge, M. Hu, G. Zhao, et al., “The “Fighting Wisdom and Bravery” of Tailed Phage and Host in the Process of Adsorption,” Microbiological Research 230 (2020): 126344.

[127] L. Yu, Y. Sun, Y. Niu, et al., “Microenvironment-Adaptive Nanozyme for Accelerating Drug-Resistant Bacteria-Infected Wound Healing,” Advanced Healthcare Materials 12, no. 10 (2023): e2202596.

[128] T. Huang, Z. Yu, B. Yuan, et al., “Synergy of Light-Controlled Pd Nanozymes With no Therapy for Biofilm Elimination and Diabetic Wound Treatment Acceleration,” Materials Today Chemistry 24 (2022): 100831.

[129] S. Fujimori, “Gastric Acid Level of Humans Must Decrease in the Future,” World Journal of Gastroenterology 26, no. 43 (2020): 6706–6709.

[130] Z. Chen, J. Yang, Q. Zhang, et al., “Inhalable Myofibroblast Targeting Nanoparticles for Synergistic Treatment of Pulmonary Fibrosis,” Science Advances 11, no. 18 (2025): eadv9571.

[131] T. Ta and T. M. Porter, “Thermosensitive Liposomes for Localized Delivery and Triggered Release of Chemotherapy,” J Control Release 169, no. 1-2 (2013): 112–125.

[132] A. S. Abu Lila and T. Ishida, “Liposomal Delivery Systems: Design Optimization and Current Applications,” Biological & Pharmaceutical Bulletin 40, no. 1 (2017): 1–10.

[133] T. M. Allen and P. R. Cullis, “Liposomal Drug Delivery Systems: From Concept to Clinical Applications,” Advanced Drug Delivery Reviews 65, no. 1 (2013): 36–48.

[134] X. Wang, Z. Xie, J. Zhao, Z. Zhu, C. Yang, and Y. Liu, “Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections,” Frontiers in Cellular and Infection Microbiology 11 (2021): 758392.

[135] S. S. Y. Leung, S. Morales, W. Britton, E. Kutter, and H. K. Chan, “Microfluidic-Assisted Bacteriophage Encapsulation Into Liposomes,” International Journal of Pharmaceutics 545, no. 1-2 (2018): 176–182.

[136] E. V. Musin, A. L. Kim, A. V. Dubrovskii, E. B. Kudryashova, E. V. Ariskina, and S. A. Tikhonenko, “The Influence of Polyanions and Polycations on Bacteriophage Activity,” Polymers (Basel) 13, no. 6 (2021): 914.

[137] P. Moghimian, V. Srot, B. P. Pichon, S. J. Facey, and P. A. V. Aken, “Stability of M13 Phage in Organic Solvents,” Journal of Biomaterials & Nanobiotechnology 07, no. 2 (2016).

[138] R. Conners, R. I. Leon-Quezada, M. McLaren, et al., “Cryo-Electron Microscopy of the F1 Filamentous Phage Reveals Insights Into Viral Infection and Assembly,” Nature Communications 14, no. 1 (2023): 2724.

[139] Z. Zhu, L. Bao, D. Pestov, P. Xu, and W. N. Wang, “Cellular-Level Insight Into Biointerface: From Surface Charge Modulation to Boosted Photocatalytic Oxidative Disinfection,” Chemical Engineering Journal 453, no. Pt 2 (2023): 139956.

[140] D. Pei and M. Buyanova, “Overcoming Endosomal Entrapment in Drug Delivery,” Bioconjugate Chemistry 30, no. 2 (2019): 273–283.

[141] M. Podlacha, L. Gaffke, L. Grabowski, et al., “Bacteriophage DNA Induces an Interrupted Immune Response during Phage Therapy in a Chicken Model,” Nature Communications 15, no. 1 (2024): 2274.

[142] S. Federici, S. Kredo-Russo, R. Valdes-Mas, et al., “Targeted Suppression of Human Ibd-Associated Gut Microbiota Commensals by Phage Consortia for Treatment of Intestinal Inflammation,” Cell 185, no. 16 (2022): 2879–2898 e24.

[143] L. Gan, Y. Feng, B. Du, et al., “Bacteriophage Targeting Microbiota Alleviates Non-Alcoholic Fatty Liver Disease Induced by High Alcohol-Producing Klebsiella Pneumoniae,” Nature Communications 14, no. 1 (2023): 3215.

[144] G. Bastin, A. Galmiche, F. Talfournier, et al., “Aerobic Conditions and Endogenous Reactive Oxygen Species Reduce the Production of Infectious Ms2 Phage by Escherichia Coli,” Viruses 13, no. 7 (2021): 1376.

[145] I. X. Yin, J. Zhang, I. S. Zhao, M. L. Mei, Q. Li, and C. H. Chu, “The Antibacterial Mechanism of Silver Nanoparticles and Its Application in Dentistry,” International Journal of Nanomedicine 15 (2020): 2555–2562.

[146] S. Qayyum, M. Oves, and A. U. Khan, “Obliteration of Bacterial Growth and Biofilm Through Ros Generation by Facilely Synthesized Green Silver Nanoparticles,” PLoS ONE 12, no. 8 (2017): e0181363.

[147] L. Xu, Y. Y. Wang, J. Huang, C. Y. Chen, Z. X. Wang, and H. Xie, “Silver Nanoparticles: Synthesis, Medical Applications and Biosafety,” Theranostics 10, no. 20 (2020): 8996–9031.

[148] H. Haidari, Z. Kopecki, R. Bright, et al., “Ultrasmall Agnp-Impregnated Biocompatible Hydrogel With Highly Effective Biofilm Elimination Properties,” ACS Applied Materials & Interfaces 12, no. 37 (2020): 41011–41025.

[149] A. Janzadeh, M. R. Hamblin, N. Janzadeh, et al., “The Toxic Effect of Silver Nanoparticles on Nerve Cells: A Systematic Review and Meta-Analysis,” Reviews of Environment Contamination and Toxicology 257 (2021): 93–119.

[150] N. N. Golosova, A. L. Matveev, N. V. Tikunova, et al., “Bacteriophage Vb_Sepp_134 and Endolysin Lysste_134_1 as Potential Staphylococcus-Biofilm-Removing Biological Agents,” Viruses 16, no. 3 (2024): 385.

[151] A. M. Pinto, M. D. Silva, L. M. Pastrana, M. Banobre-Lopez, and S. Sillankorva, “The Clinical Path to Deliver Encapsulated Phages and Lysins,” Fems Microbiology Review 45, no. 5 (2021): fuab019.

[152] V. S. Gondil, T. Dube, J. J. Panda, R. M. Yennamalli, K. Harjai, and S. Chhibber, “Comprehensive Evaluation of Chitosan Nanoparticle Based Phage Lysin Delivery System; a Novel Approach to Counter S. Pneumoniae Infections,” International Journal of Pharmaceutics 573 (2020): 118850.

[153] J. Kaur, A. Kour, J. J. Panda, K. Harjai, and S. Chhibber, “Exploring Endolysin-Loaded Alginate-Chitosan Nanoparticles as Future Remedy for Staphylococcal Infections,” Aaps Pharmscitech [Electronic Resource] 21, no. 6 (2020): 233.

[154] H. Liu, X. Wei, H. Peng, et al., “Lyssyl-Loaded Ph-Switchable Self-Assembling Peptide Hydrogels Promote Methicillin-Resistant Staphylococcus Aureus Elimination and Wound Healing,” Advanced Materials 36, no. 52 (2024): e2412154.

[155] J. Bai, E. Yang, P. S. Chang, and S. Ryu, “Preparation and Characterization of Endolysin-Containing Liposomes and Evaluation of Their Antimicrobial Activities Against Gram-Negative Bacteria,” Enzyme and Microbial Technology 128 (2019): 40–48.

[156] H. Ning, J. Zhang, Q. Zhao, H. Lin, and J. Wang, “Development of the Phage Lysin-Loaded Liposomes as Preservatives for Live Clams,” International Journal of Food Microbiology 387 (2023): 110059.

[157] D. Morais, L. Tanoeiro, A. T. Marques, et al., “Liposomal Delivery of Newly Identified Prophage Lysins in a Pseudomonas Aeruginosa Model,” International Journal of Molecular Sciences 23, no. 17 (2022): 10143.

[158] C. Li, R. Nyaruaba, X. Zhao, et al., “Thermosensitive Hydrogel Wound Dressing Loaded With Bacteriophage Lysin Lysp53,” Viruses 14, no. 9 (2022): 1956.

[159] H. Wang, Y. Liu, C. Bai, and S. S. Y. Leung, “[Not Available],” Acta Pharmaceutica Sinica B 14, no. 1 (2024): 155–169.

[160] G. Topka-Bielecka, A. Dydecka, A. Necel, et al., “Bacteriophage-Derived Depolymerases Against Bacterial Biofilm,” Antibiotics (Basel) 10, no. 2 (2021): 175.

[161] A. Ringaci, K. G. Shevchenko, I. V. Zelepukin, A. V. Popova, and M. P. Nikitin, “Phage-Mimicking Nanoagents for Rapid Depolymerase Specificity Screening Against Multidrug Resistant Bacteria,” Biosensors & Bioelectronics 213 (2022): 114444.

[162] C. Wang, S. Wang, S. Jing, et al., “Data-Driven Engineering of Phages With Tunable Capsule Tropism for Klebsiella Pneumoniae,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 11, no. 33 (2024): e2309972.

[163] J. Song, Z. Liu, Q. Zhang, Y. Liu, and Y. Chen, “Phage Engineering for Targeted Multidrug-Resistant Escherichia Coli,” International Journal of Molecular Sciences 24, no. 3 (2023): 2459.

[164] P. Huss, K. Kieft, A. Meger, K. Nishikawa, K. Anantharaman, and S. Raman, “Engineering Bacteriophages Through Deep Mining of Metagenomic Motifs,” Science Advances 11, no. 16 (2025): eadt6432.

[165] Y. E. Gencay, D. Jasinskyt, C. Robert, et al., “Engineered Phage With Antibacterial Crispr-Cas Selectively Reduce E. Coli Burden in Mice,” Nature Biotechnology 42, no. 2 (2023): 265–274.

[166] G. Tonkin-Hill, C. Ruis, S. D. Bentley, K. A. Lythgoe, and J. M. Bryant, “Within-Host Bacterial Evolution and the Emergence of Pathogenicity,” Nature Microbiology 10, no. 8 (2025): 1829–1840.

[167] H. Zhang, D. E. Fouts, J. DePew, and R. H. Stevens, “Genetic Modifications to Temperate Enterococcus Faecalis Phage Ef11 That Abolish the Establishment of Lysogeny and Sensitivity to Repressor, and Increase Host Range and Productivity of Lytic Infection,” Microbiology (Reading, England) 159, no. Pt 6 (2013): 1023–1035.

[168] R. Monteiro, D. P. Pires, A. R. Costa, and J. Azeredo, “Phage Therapy: Going Temperate?,” Trends in Microbiology 27, no. 4 (2019): 368–378.

[169] J. M. Tinoco, B. Buttaro, H. Zhang, N. Liss, L. Sassone, and R. Stevens, “Effect of a Genetically Engineered Bacteriophage on Enterococcus Faecalis Biofilms,” Archives of Oral Biology 71 (2016): 80–86.

[170] J. M. Tinoco, N. Liss, H. Zhang, et al., “Antibacterial Effect of Genetically-Engineered Bacteriophage ?Ef11/?Fl1c(Δ36)P(Nisa) on Dentin Infected With Antibiotic-Resistant Enterococcus Faecalis,” Archives of Oral Biology 82 (2017): 166–170.

[171] J. Guan, A. Oromí-Bosch, S. D. Mendoza, S. Karambelkar, J. D. Berry, and J. Bondy-Denomy, “Bacteriophage Genome Engineering With Crispr-Cas13a,” Nature Microbiology 7, no. 12 (2022): 1956–1966.

[172] B. A. Adler, T. Hessler, B. F. Cress, et al., “Broad-Spectrum Crispr-Cas13a Enables Efficient Phage Genome Editing,” Nature Microbiology 7, no. 12 (2022): 1967–1979.

[173] L. H. Cobb, J. Park, E. A. Swanson, et al., “Crispr-Cas9 Modified Bacteriophage for Treatment of Staphylococcus Aureus Induced Osteomyelitis and Soft Tissue Infection,” PLoS ONE 14, no. 11 (2019): e0220421.

[174] L. J. Marinelli, M. Piuri, Z. Swigonová, et al., “Bred: A Simple and Powerful Tool for Constructing Mutant and Recombinant Bacteriophage Genomes,” PLoS ONE 3, no. 12 (2008): e3957.

[175] D. Bikard, C. W. Euler, W. Jiang, et al., “Exploiting Crispr-Cas Nucleases to Produce Sequence-Specific Antimicrobials,” Nature Biotechnology 32, no. 11 (2014): 1146–1150.

[176] K. Selle, J. R. Fletcher, H. Tuson, et al., “In Vivo Targeting of Clostridioides Difficile Using Phage-Delivered Crispr-Cas3 Antimicrobials,” MBio 11, no. 2 (2020): e00019–20.

[177] S. Mitsunaka, K. Yamazaki, A. K. Pramono, et al., “Synthetic Engineering and Biological Containment of Bacteriophages,” Proceedings of the National Academy of Sciences of the United States of America 119, no. 48 (2022): e2206739119.

[178] J. Martorell-Marugán, S. Tabik, Y. Benhammou, et al., “Computational Biology,” Brisbane (AU) (2019).

[179] H. J. Coleman, Q. Yang, A. Robert, et al., “Formulation of Three Tailed Bacteriophages by Spray-Drying and Atomic Layer Deposition for Thermal Stability and Controlled Release,” Journal of Pharmaceutical Sciences 113, no. 11 (2024): 3238–3245.

[180] S. Lemire, K. M. Yehl, and T. K. Lu, “Phage-Based Applications in Synthetic Biology,” Annual Review of Virology 5, no. 1 (2018): 453–476.

[181] D. G. Gibson, L. Young, R. Y. Chuang, J. C. Venter, C. A. Hutchison, and H. O. Smith, “Enzymatic Assembly of DNA Molecules up to Several Hundred Kilobases,” Nature Methods 6, no. 5 (2009): 343–345.

[182] S. Kilcher, P. Studer, C. Muessner, J. Klumpp, and M. J. Loessner, “Cross-Genus Rebooting of Custom-Made, Synthetic Bacteriophage Genomes in L-Form Bacteria,” Proceedings of the National Academy of Sciences of the United States of America 115, no. 3 (2018): 567–572.

[183] M. Rustad, A. Eastlund, P. Jardine, and V. Noireaux, “Cell-Free Txtl Synthesis of Infectious Bacteriophage T4 in a Single Test Tube Reaction,” Synthetic Biology (Oxford, England) 3, no. 1 (2018): ysy002.

[184] Q. Emslander, K. Vogele, P. Braun, et al., “Cell-Free Production of Personalized Therapeutic Phages Targeting Multidrug-Resistant Bacteria,” Cell Chemical Biology 29, no. 9 (2022): 1434–1445.e7.

[185] N. Cecchini, M. Schmerer, I. J. Molineux, R. Springman, and J. J. Bull, “Evolutionarily Stable Attenuation by Genome Rearrangement in a Virus,” G3 (Bethesda, Md) 3, no. 8 (2013): 1389–1397.

[186] K. Bodner, A. L. Melkonian, and M. W. Covert, “The Enemy of My Enemy: New Insights Regarding Bacteriophage-Mammalian Cell Interactions,” Trends in Microbiology 29, no. 6 (2021): 528–541.

[187] K. R. Shrestha, S. Kim, A. Jo, M. Ragothaman, and S. Y. Yoo, “In Vivo Safety Evaluation and Tracing of Arginylglycylaspartic Acid-Engineered Phage Nanofiber in Murine Model,” Journal of Materials Chemistry B 12, no. 40 (2024): 10258–10271.

[188] A. Nair and K. Khairnar, “Genetically Engineered Phages for Therapeutics: Proceed With Caution,” Nature Medicine 25, no. 7 (2019): 1028.

[189] S. Kilcher and M. J. Loessner, “Engineering Bacteriophages as Versatile Biologics,” Trends in Microbiology 27, no. 4 (2019): 355–367.

[190] P. Kendra, “Rumbaugh, and Sauer Karin. Biofilm Dispersion,” Nature Reviews Microbiology 18, no. 10 (2020): 571–586.

[191] K. Fabian, C. Claudia, W. Jeroen, et al., “Targeting Pseudomonas Aeruginosa Biofilm With an Evolutionary Trained Bacteriophage Cocktail Exploiting Phage Resistance Trade-Offs,” Nature Communications 15, no. 1 (2024): 8572.

[192] H. Alexander, M. Etienne, and G. Kenn, “Mechanisms of Bacterial Persistence during Stress and Antibiotic Exposure,” Science (New York, NY) 354, no. 6318 (2016): aaf4268.

[193] J. Bigger, “Treatment of Staphylococcal Infections With Penicillin by Intermittent Steriliasation,” The Lancet 244, no. 6320 (1944): 497–500.

[194] W. P. J. Smith, B. R. Wucher, C. D. Nadell, and K. R. Foster, “Bacterial Defences: Mechanisms, Evolution and Antimicrobial Resistance,” Nature Reviews Microbiology 21, no. 8 (2023): 519–534.

[195] A. Mayorga-Ramos, S. E. Carrera-Pacheco, C. Barba-Ostria, and L. P. Guamán, “Bacteriophage-Mediated Approaches for Biofilm Control,” Frontiers in Cellular and Infection Microbiology 14 (2024): 1428637.

[196] A. C. Hernandez-Morales, L. L. Lessor, T. L. Wood, et al., “Genomic and Biochemical Characterization of Acinetobacter Podophage Petty Reveals a Novel Lysis Mechanism and Tail-Associated Depolymerase Activity,” Journal of Virology 92, no. 6 (2018): e01064–e01217.

[197] M. Shahed-Al-Mahmud, R. Roy, F. G. Sugiokto, et al., “Phage Φab6-Borne Depolymerase Combats Acinetobacter Baumannii Biofilm Formation and Infection,” Antibiotics (Basel, Switzerland) 10, no. 3 (2021): 279.

[198] T. Fengjuan, L. Jing, N. Amina, and T. Yigang, “Bacteriophage—a Promising Alternative Measure for Bacterial Biofilm Control,” Infection and Drug Resistance 14 (2021): 205–217.

[199] E. Maffei, A. K. Woischnig, M. R. Burkolter, et al., “Phage Paride Can Kill Dormant, Antibiotic-Tolerant Cells of Pseudomonas Aeruginosa by Direct Lytic Replication,” Nature Communications 15, no. 1 (2024): 175.

[200] L. Meneses, L. Valentová, B. Santos Sílvio, et al., “Directed Evolution of Phages in Biofilms Enhances Pseudomonas Aeruginosa Control Through Improved Lipopolysaccharide Recognition,” Nature Communications 16, no. 1 (2025): 10219.

[201] E. L. Doughty, H. Liu, R. A. Moran, et al., “Endemicity and Diversification of Carbapenem-Resistant Acinetobacter Baumannii in an Intensive Care Unit,” The Lancet Regional Health Western Pacific 37 (2023): 100780.

[202] H. Liu, R. A. Moran, E. L. Doughty, et al., “Longitudinal Genomics Reveals Carbapenem-Resistant Acinetobacter Baumannii Population Changes With Emergence of Highly Resistant St164 Clone,” Nature Communications 15, no. 1 (2024): 9483.

[203] P.-M. Marcos, L. David, E. Stefan, D. G. Joakim Larsson, J. Anna, and K. Erik, “The Transfer of Antibiotic Resistance Genes Between Evolutionarily Distant Bacteria,” mSphere 10, no. 6 (2025): e0011425.

[204] K. R. Chng, C. Li, D. Bertrand, et al., “Cartography of Opportunistic Pathogens and Antibiotic Resistance Genes in a Tertiary Hospital Environment,” Nature Medicine 26, no. 6 (2020): 941–951.

[205] L. W. Roberts, B. M. Forde, T. Hurst, et al., “Genomic Surveillance, Characterization and Intervention of a Polymicrobial Multidrug-Resistant Outbreak in Critical Care,” Microbial Genomics 7, no. 3 (2021): mgen000530.

[206] J. Chen, L. Ji, G. Xiong, and K. Ning, “The Distinct Microbial Community Patterns and Pathogen Transmission Routes in Intensive Care Units,” Journal of Hazardous Materials 441 (2023): 129964.

[207] F. Medioli, E. Bacca, and M. Faltoni, “Is It Possible to Eradicate Carbapenem-Resistant Acinetobacter Baumannii (Crab) From Endemic Hospitals?,” Antibiotics (Basel, Switzerland) 11, no. 8 (2022): 1015.

[208] H. Seok, J. H. Jeon, J. H. Jung, et al., “Does Enhanced Environmental Cleaning Reduce Carbapenem-Resistant Acinetobacter Baumannii Colonization in the Intensive Care Unit?,” International Journal of Infectious Diseases 109 (2021): 72–76.

[209] D. Nizami, T. Muhyittin, D. G. Gülbol, E. L. Naciye, and J. Kemal, “Relationship Between the Resistance Genes to Quaternary Ammonium Compounds and Antibiotic Resistance in Staphylococci Isolated From Surgical Site Infections,” Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 20 (2014): 544–550.

[210] D. J. Anderson, L. F. Chen, D. J. Weber, et al., “Enhanced Terminal Room Disinfection and Acquisition and Infection Caused by Multidrug-Resistant Organisms and Clostridium Difficile (the Benefits of Enhanced Terminal Room Disinfection Study): A Cluster-Randomised, Multicentre, Crossover Study,” Lancet (London, England) 389, no. 10071 (2017): 805–814.

[211] S. Dhar, C. Jinadatha, P. E. Kilgore, et al., “Lowering the Acquisition of Multidrug-Resistant Organisms (Mdros) With Pulsed-Xenon (Lamp) Study: A Cluster-Randomized, Controlled, Double-Blinded, Interventional Crossover Trial,” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 79, no. 4 (2024): 1024–1030.

[212] Y. H. Ho, C. C. Tseng, L. S. Wang, et al., “Application of Bacteriophage-Containing Aerosol Against Nosocomial Transmission of Carbapenem-Resistant Acinetobacter Baumannii in an Intensive Care Unit,” PLoS ONE 11, no. 12 (2016): e0168380.

[213] L. K. Chen, J. C. Chang, H. T. Chu, et al., “Preoptimized Phage Cocktail for Use in Aerosols Against Nosocomial Transmission of Carbapenem-Resistant Acinetobacter Baumannii: A 3-Year Prospective Intervention Study,” Ecotoxicology and Environmental Safety 236 (2022): 113476.

[214] Y. Shi, W. Zhang, L. Li, et al., “Evaluation of Phage-Based Decontamination in Respiratory Intensive Care Unit Environments Using Ddpcr and 16s Rrna Targeted Sequencing Techniques,” Frontiers in Cellular and Infection Microbiology 14 (2024): 1442062.

[215] M. D'Accolti, I. Soffritti, L. Lanzoni, et al., “Effective Elimination of Staphylococcal Contamination From Hospital Surfaces by a Bacteriophage-Probiotic Sanitation Strategy: A Monocentric Study,” Microbial Biotechnology 12, no. 4 (2019): 742–751.

[216] C. N. Zongyue, Y. Yuhui, L. Gaoming, H. Youying, L. Yu, and L. Shuai, “Effective Elimination of Bacteria on Hard Surfaces by the Combined Use of Bacteriophages and Chemical Disinfectants,” Microbiology Spectrum 12, no. 4 (2024): e0379723.

[217] A. Seila, F. Lucía, G.-M. Eva, M. Beatriz, R. Ana, and G. Pilar, “Study of the Interactions Between Bacteriophage Phiipla-Rodi and Four Chemical Disinfectants for the Elimination of Staphylococcus Aureus Contamination,” Viruses 10, no. 3 (2018): 103.

[218] S. Elyse, K. Anina, and R. J. Timothy, “Bacteriophage Treatment Before Chemical Disinfection Can Enhance Removal of Plastic-Surface-Associated Pseudomonas Aeruginosa,” Applied and Environmental Microbiology 87, no. 20 (2021): e0098021.

[219] D. Tomat, C. Balagué, V. Aquili, R. Verdini, and A. Quiberoni, “Resistance of Phages Lytic to Pathogenic Escherichia Coli to Sanitisers Used by the Food Industry and in Home Settings,” International Journal of Food Science & Technology 53, no. 2 (2018): 533–540.

[220] J. J. Dennehy and T. Stephen, “Abedon,” Phage Infection and Lysis (2021): 341–383.

[221] G. Catho, R. Martischang, F. Boroli, et al., “Outbreak of Pseudomonas Aeruginosa Producing Vim Carbapenemase in an Intensive Care Unit and Its Termination by Implementation of Waterless Patient Care,” Critical Care (London, England) 25, no. 1 (2021): 301.

[222] G. E. McCallum and J. P. J. Hall, “The Hospital Sink Drain Microbiome as a Melting Pot for Amr Transmission to Nosocomial Pathogens,” npj Antimicrobials and Resistance 3, no. 1 (2025): 68.

[223] T. E. Klassert, C. Zubiria-Barrera, R. Neubert, et al., “Comparative Analysis of Surface Sanitization Protocols on the Bacterial Community Structures in the Hospital Environment,” Clinical Microbiology and Infection 28, no. 8 (2022): 1105–1112.

[224] G. Catho, C. Cave, R. Grant, et al., “Controlling the Hospital Aquatic Reservoir of Multidrug-Resistant Organisms: A Cross-Sectional Study Followed by a Nested Randomized Trial of Sink Decontamination,” Clinical Microbiology and Infection 30, no. 8 (2024): 1049–1054.

[225] S. Kotay, W. Chai, W. Guilford, K. Barry, and A. J. Mathers, “Spread From the Sink to the Patient: In Situ Study Using Green Fluorescent Protein (Gfp)-Expressing Escherichia Coli to Model Bacterial Dispersion From Hand-Washing Sink-Trap Reservoirs,” Applied and Environmental Microbiology 83, no. 8 (2017): e03327–e03416.

[226] K. Ledwoch, A. Robertson, J. Lauran, P. Norville, and J. Y. Maillard, “It's a Trap! the Development of a Versatile Drain Biofilm Model and Its Susceptibility to Disinfection,” Journal of Hospital Infection 106, no. 4 (2020): 757–764.

[227] M. Ji, Z. Liu, K. Sun, Z. Li, X. Fan, and Q. Li, “Bacteriophages in Water Pollution Control: Advantages and Limitations,” Frontiers of Environmental Science & Engineering 15, no. 5 (2020): 84.

[228] M. D. Zapata-Montoya, L. Salazar-Ospina, and J. N. Jiménez, “Combating Environmental Antimicrobial Resistance Using Bacteriophage Cocktails Targeting Β-Lactam-Resistant High-Risk Clones of Klebsiella Pneumoniae and Escherichia Coli in Wastewater: A Strategy for Treatment and Reuse,” Water 17, no. 15 (2025): 2236.

[229] S. Sadeqi, A. Hashemi Shahraki, F. Nikkhahi, A. Javadi, and S. M. Amin Marashi, “Application of Bacteriophage Cocktails for Reducing the Bacterial Load of Nosocomial Pathogens in Hospital Wastewater,” Iranian Journal of Microbiology 14, no. 3 (2022): 395–401.

[230] K. B. Shivaram, P. Bhatt, B. Applegate, and H. Simsek, “Bacteriophage-Based Biocontrol Technology to Enhance the Efficiency of Wastewater Treatment and Reduce Targeted Bacterial Biofilms,” Science of The Total Environment 862 (2023): 160723.

[231] J. Chen, S. D. Alcaine, Z. Jiang, V. M. Rotello, and S. R. Nugen, “Detection of Escherichia Coli in Drinking Water Using T7 Bacteriophage-Conjugated Magnetic Probe,” Analytical Chemistry 87, no. 17 (2015): 8977–8984.

[232] F. Bayat, T. F. Didar, and Z. Hosseinidoust, “Emerging Investigator Series: Bacteriophages as Nano Engineering Tools for Quality Monitoring and Pathogen Detection in Water and Wastewater,” Environmental Science: Nano 8, no. 2 (2021): 367–389.

[233] W. Huang, F. Wang, Y. Su, H. Huang, and J. Luo, “Underestimated Roles of Phages in Biological Wastewater Treatment Systems: Recent Advances and Challenges,” Journal of Hazardous Materials 495 (2025): 139007.

[234] X. Fan, M. Ji, K. Sun, and Q. Li, “Microbial and Phage Communities as Well as Their Interaction in Po Saponification Wastewater Treatment Systems,” Water Science and Technology 87, no. 2 (2023): 354–365.

[235] X. Shuai, Z. Zhou, X. Ba, et al., “Bacteriophages: Vectors of or Weapons Against the Transmission of Antibiotic Resistance Genes in Hospital Wastewater Systems?,” Water Research 248 (2024): 120833.

[236] L. D. Shi, X. Dong, Z. Liu, et al., “A Mixed Blessing of Viruses in Wastewater Treatment Plants,” Water Research 215 (2022): 118237.

[237] D. Piel, M. Bruto, Y. Labreuche, et al., “Phage-Host Coevolution in Natural Populations,” Nature Microbiology 7, no. 7 (2022): 1075–1086.

[238] M. Hu, B. Xing, M. Yang, et al., “Characterization of a Novel Genus of Jumbo Phages and Their Application in Wastewater Treatment,” Iscience 26, no. 6 (2023): 106947.

[239] A. Salim, A. Madhavan, S. Subhash, M. Prasad, B. G. Nair, and S. Pal, “Escherichia Coli St155 as a Production-Host of Three Different Polyvalent Phages and Their Characterisation With a Prospect for Wastewater Disinfection,” Scientific Reports 12, no. 1 (2022): 19406.

[240] A. Gupta, A. Rudra, K. Reed, R. Langer, and D. G. Anderson, “Advanced Technologies for the Development of Infectious Disease Vaccines,” Nature Reviews Drug Discovery 23, no. 12 (2024): 914–938.

[241] Q. Bao, X. Li, G. Han, Y. Zhu, C. Mao, and M. Yang, “Phage-Based Vaccines,” Advanced Drug Delivery Reviews 145 (2019): 40–56.

[242] L. Ledsgaard, A. Ljungars, C. Rimbault, et al., “Advances in Antibody Phage Display Technology,” Drug Discovery Today 27, no. 8 (2022): 2151–2169.

[243] T. Anand, N. Virmani, B. C. Bera, et al., “Phage Display Technique as a Tool for Diagnosis and Antibody Selection for Coronaviruses,” Current Microbiology 78, no. 4 (2021): 1124–1134.

[244] O. I. Guliy, S. S. Evstigneeva, and L. A. Dykman, “Recombinant Antibodies by Phage Display for Bioanalytical Applications,” Biosensors & Bioelectronics 222 (2023): 114909.

[245] Q. Jia and Y. Xiang, “Author Correction: Cryo-Em Structure of a Bacteriophage M13 Mini Variant,” Nature Communications 14, no. 1 (2023): 8433.

[246] I. D. Hay and T. Lithgow, “Filamentous Phages: Masters of a Microbial Sharing Economy,” Embo Reports 20, no. 6 (2019): e47427.

[247] Y. Wan, Y. Wu, J. Bian, et al., “Induction of Hepatitis B Virus-Specific Cytotoxic T Lymphocytes Response in Vivo by Filamentous Phage Display Vaccine,” Vaccine 19, no. 20-22 (2001): 2918–2923.

[248] F. Wang, S. Chen, Y. Xia, et al., “Dual-Engineered Phage Vaccine Platform Facilitates Sting Activation for Influenza Protection,” ACS Applied Materials & Interfaces 17, no. 1 (2025): 419–429.

[249] W. Jaroszewicz, J. Morcinek-Orlowska, K. Pierzynowska, L. Gaffke, and G. Wegrzyn, “Phage Display and Other Peptide Display Technologies,” Fems Microbiology Review 46, no. 2 (2022): fuab052.

[250] P. E. Saw and E. W. Song, “Phage Display Screening of Therapeutic Peptide for Cancer Targeting and Therapy,” Protein Cell 10, no. 11 (2019): 787–807.

[251] H. Yue, Y. Li, M. Yang, and C. Mao, “T7 Phage as an Emerging Nanobiomaterial With Genetically Tunable Target Specificity,” Advanced Science (Weinheim) 9, no. 4 (2022): e2103645.

[252] J. Zhu, P. Tao, A. K. Chopra, and V. B. Rao, “Bacteriophage T4 as a Protein-Based, Adjuvant- and Needle-Free, Mucosal Pandemic Vaccine Design Platform,” Annual Review of Virology 11, no. 1 (2024): 395–420.

[253] H. Hashemi, S. Pouyanfard, M. Bandehpour, et al., “Immunization With M2e-Displaying T7 Bacteriophage Nanoparticles Protects Against Influenza a Virus Challenge,” PLoS ONE 7, no. 9 (2012): e45765.

[254] P. Tao, M. Mahalingam, J. Zhu, et al., “A Bacteriophage T4 Nanoparticle-Based Dual Vaccine Against Anthrax and Plague,” MBio 9, no. 5 (2018): e01926–e01928.

[255] J. Zhu, S. Jain, J. Sha, et al., “A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal Covid-19 Vaccine,” MBio 13, no. 4 (2022): e0182222.

[256] H. Yue, Y. Li, T. Yang, et al., “Filamentous Phages as Tumour-Targeting Immunotherapeutic Bionanofibres,” Nature Nanotechnology 20, no. 1 (2025): 167–176.

[257] S. Huang, Y. He, A. Madow, et al., “A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer Vaccine and Therapy,” Advanced Materials 37, no. 43 (2025): e10229.

[258] N. J. Tursi, S. Tiwari, N. Bedanova, et al., “Modulation of Lipid Nanoparticle-Formulated Plasmid DNA Drives Innate Immune Activation Promoting Adaptive Immunity,” Cell Reports Medicine 6, no. 4 (2025): 102035.

[259] X. Ge and J. Wang, “Structural Mechanism of Bacteriophage Lambda Tail's Interaction With the Bacterial Receptor,” Nature Communications 15, no. 1 (2024): 4185.

[260] H. Hashemi, T. Bamdad, A. Jamali, S. Pouyanfard, and M. G. Mohammadi, “Evaluation of Humoral and Cellular Immune Responses Against Hsv-1 Using Genetic Immunization by Filamentous Phage Particles: A Comparative Approach to Conventional DNA Vaccine,” Journal of Virological Methods 163, no. 2 (2010): 440–444.

[261] J. B. March, J. R. Clark, and C. D. Jepson, “Genetic Immunisation Against Hepatitis B Using Whole Bacteriophage Lambda Particles,” Vaccine 22, no. 13-14 (2004): 1666–1671.

[262] A. Ghaemi, H. Soleimanjahi, P. Gill, Z. Hassan, S. R. Jahromi, and F. Roohvand, “Recombinant Lambda-Phage Nanobioparticles for Tumor Therapy in Mice Models,” Genetic Vaccines and Therapy 8 (2010): 3.

[263] J. R. Clark, K. Bartley, C. D. Jepson, V. Craik, and J. B. March, “Comparison of a Bacteriophage-Delivered DNA Vaccine and a Commercially Available Recombinant Protein Vaccine Against Hepatitis B,” Fems Immunology and Medical Microbiology 61, no. 2 (2011): 197–204.

[264] H. Xu, R. Li, J. Zhang, et al., “Construction of T7 Phage Mediated Eukaryotic Expression Vector Transport Platform,” Acta Microbiologica Sinica 62, no. 03 (2022): 982–992.

[265] J. Su, J. Zhang, X. Feng, et al., “A Universal Viral Capsid Protein Based One Step Rna Synthesis and Packaging System for Rapid and Efficient Mrna Vaccine Development,” Molecular Therapy 33, no. 4 (2025): 1720–1734.

[266] H. Langbeheim, D. Teitelbaum, and R. Arnon, “Cellular Immune Response Toward Ms-2 Phage and a Synthetic Fragment of Its Coat Protein,” Cellular Immunology 38, no. 1 (1978): 193–197.

[267] M. Bernabeu-Gimeno, M. Pardo-Freire, B. K. Chan, et al., “Neutralizing Antibodies After Nebulized Phage Therapy in Cystic Fibrosis Patients,” Med 5, no. 9 (2024): 1096–1111 e6.

[268] M. Gangwar, S. Rastogi, D. Singh, et al., “Immunological and Safety Profile of Bacteriophage Therapy: A Pre-Clinical Study,” Journal of Applied Microbiology 133, no. 3 (2022): 1446–1460.

[269] A. Petrovic Fabijan, R. C. Y. Lin, J. Ho, et al., “Publisher Correction: Safety of Bacteriophage Therapy in Severe Staphylococcus Aureus Infection,” Nature Microbiology 5, no. 4 (2020): 652.

[270] J. Singh, S. Lynch, J. Iredell, and H. Selvadurai, “Safety and Tolerability of Bronchoscopic and Nebulised Administration of Bacteriophage,” Virus Research 348 (2024): 199442.

[271] E. El-Din, B. M. Zaki, A. M. A. El-Aziz, and Y. M. Ali, “Bacteriophage-Antibiotic Synergy Enhances Therapeutic Efficacy Against Multidrug-Resistant Klebsiella Pneumoniae Infections,” Journal of Applied Microbiology 136, no. 6 (2025): lxaf131.

[272] C. Duplessis, J. M. Warawa, M. B. Lawrenz, M. Henry, and B. Biswas, “Successful Intratracheal Treatment of Phage and Antibiotic Combination Therapy of a Multi-Drug Resistant Pseudomonas Aeruginosa Murine Model,” Antibiotics (Basel) 10, no. 8 (2021): 946.

[273] H. J. Jia, P. P. Jia, S. Yin, L. K. Bu, G. Yang, and D. S. Pei, “Engineering Bacteriophages for Enhanced Host Range and Efficacy: Insights From Bacteriophage-Bacteria Interactions,” Frontiers in Microbiology 14 (2023): 1172635.

[274] M. J. Karau, S. M. Schmidt-Malan, Q. Yan, et al., “Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus Aureus Osteomyelitis in Rats,” Antimicrobial Agents and Chemotherapy 63, no. 10 (2019): e01235–e01239.

[275] J. P. Gonzalez-Gomez, B. Gonzalez-Torres, P. J. Guerrero-Medina, et al., “Efficacy of Novel Bacteriophages Against Escherichia Coli Biofilms on Stainless Steel,” Antibiotics (Basel) 10, no. 10 (2021): 1150.

[276] M. Titecat, C. Rousseaux, C. Dubuquoy, et al., “Safety and Efficacy of an Aiec-Targeted Bacteriophage Cocktail in a Mice Colitis Model,” Journal of Crohn's and Colitis 16, no. 10 (2022): 1617–1627.

[277] J. Singh, D. A. Fitzgerald, A. Jaffe, et al., “Single-Arm, Open-Labelled, Safety and Tolerability of Intrabronchial and Nebulised Bacteriophage Treatment in Children With Cystic Fibrosis and Pseudomonas Aeruginosa,” BMJ Open Respiratory Research 10, no. 1 (2023): e001360.

[278] V. B. Yadav and G. Nath, “Bacteriophage Therapy of Human-Restricted Salmonella Species-a Study in a Surrogate Bacterial and Animal Model,” Letters in Applied Microbiology 75, no. 2 (2022): 422–430.

[279] J. B. Doub, V. Y. Ng, M. Lee, et al., “Salphage: Salvage Bacteriophage Therapy for Recalcitrant Mrsa Prosthetic Joint Infection,” Antibiotics (Basel) 11, no. 5 (2022): 616.

[280] K. M. Chung, S. C. Nang, and S. S. Tang, “The Safety of Bacteriophages in Treatment of Diseases Caused by Multidrug-Resistant Bacteria,” Pharmaceuticals (Basel) 16, no. 10 (2023): 1347.

[281] M. W. Calfee, S. P. Ryan, A. Abdel-Hady, et al., “Virucidal Efficacy of Antimicrobial Surface Coatings Against the Enveloped Bacteriophage Phi6,” Journal of Applied Microbiology 132, no. 3 (2022): 1813–1824.

[282] F. Kunisch, C. Campobasso, J. Wagemans, et al., “Targeting Pseudomonas Aeruginosa Biofilm With an Evolutionary Trained Bacteriophage Cocktail Exploiting Phage Resistance Trade-Offs,” Nature Communications 15, no. 1 (2024): 8572.

[283] N. Law, C. Logan, G. Yung, et al., “Successful Adjunctive Use of Bacteriophage Therapy for Treatment of Multidrug-Resistant Pseudomonas Aeruginosa Infection in a Cystic Fibrosis Patient,” Infection 47, no. 4 (2019): 665–668.

[284] Y. Yang, X. Tan, M. Xiong, et al., “A Case Report of Bacteriophage Therapy for the Treatment of Lung Infection due to Carbapenem-Resistant Pseudomonas Aeruginosa,” Scientific Reports 15, no. 1 (2025): 33512.

[285] A. V. Johri, P. Johri, N. Hoyle, L. Pipia, L. Nadareishvili, and D. Nizharadze, “Case Report: Chronic Bacterial Prostatitis Treated With Phage Therapy After Multiple Failed Antibiotic Treatments,” Frontiers in Pharmacology 12 (2021): 692614.

[286] A. V. Johri, P. Johri, N. Hoyle, L. Nadareishvili, L. Pipia, and D. Nizharadze, “Case Report: Successful Treatment of Recurrent E. Coli Infection With Bacteriophage Therapy for Patient Suffering From Chronic Bacterial Prostatitis,” Frontiers in Pharmacology 14 (2023): 1243824.

[287] R. Nir-Paz and E. J. Kuijper, “Bacteriophage Therapy in Humans,” Clinical Microbiology and Infection 29, no. 6 (2023): 679–681.

[288] B. P. Gibb and M. Hadjiargyrou, “Bacteriophage Therapy for Bone and Joint Infections,” Bone & Joint Journal 103-B, no. 2 (2021): 234–244.

[289] J. N. Zurita-Cruz, L. Barbosa-Cortes, and M. A. Villasis-Keever, “[From Research to Practice: Clinical Phases for Drug Development],” Revista Alergia Mexico 66, no. 2 (2019): 246–253.

[290] T. Luong, A. C. Salabarria, R. A. Edwards, and D. R. Roach, “Standardized Bacteriophage Purification for Personalized Phage Therapy,” Nature Protocols 15, no. 9 (2020): 2867–2890.

[291] B. K. Chan, G. Stanley, M. Modak, J. L. Koff, and P. E. Turner, “Bacteriophage Therapy for Infections in Cf,” Pediatric Pulmonology 56, no. Suppl 1 (2021): S4–S9.

[292] C. Venturini, A. Petrovic Fabijan, A. Fajardo Lubian, S. Barbirz, and J. Iredell, “Biological Foundations of Successful Bacteriophage Therapy,” EMBO Molecular Medicine 14, no. 7 (2022): e12435.

[293] E. Laanto, “Overcoming Bacteriophage Resistance in Phage Therapy,” Methods in Molecular Biology 2738 (2024): 401–410.

[294] S. K. Niazi, “Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways,” Pharmaceuticals (Basel) 18, no. 8 (2025): 1115.

[295] N. Cesta, M. Di Luca, M. Corbellino, M. Tavio, M. Galli, and M. Andreoni, “Bacteriophage Therapy: An Overview and the Position of Italian Society of Infectious and Tropical Diseases,” Le Infezioni in Medicina 28, no. 3 (2020): 322–331.

[296] T. A. Ahmad, S. E. Houjeiry, S. S. Kanj, G. M. Matar, and E. S. Saba, “From Forgotten Cure to Modern Medicine: The Resurgence of Bacteriophage Therapy,” Journal of Global Antimicrobial Resistance 39 (2024): 231–239.

[297] R. Bernabe, S. A. Dawkins-Cox, and C. C. Gispen-de Wied, “Gaps in the Ethical Governance of Pharmaceutical Clinical Trials in Europe,” Frontiers in Medicine (Lausanne) 11 (2024): 1507021.

[298] N. Ghimire, R. Basnet, R. Acharya, S. Adhikari, S. Verma, and M. R. Sharma, “World Health Organization Tool for Benchmarking Ethics Oversight of Health-Related Research With Human Participants,” JNMA Journal of Nepal Medical Association 62, no. 280 (2024): 862–865.

[299] F. M. Aldhafeeri, “Governing Artificial Intelligence in Radiology: A Systematic Review of Ethical, Legal, and Regulatory Frameworks,” Diagnostics (Basel) 15, no. 18 (2025): 2300.

[300] B. J. Evans and A. Bihorac, “Co-Creating Consent for Data Use—Ai-Powered Ethics for Biomedical Ai,” NEJMAI 1, no. 7 (2024): aipc2400237.

[301] C. Adebamowo, A. Akintola, O. C. Maduka, et al., “Knowledge and Recommendations of Stakeholders Regarding Ethical Oversight of Data Science Health Research: A Qualitative Study Protocol,” JMIR Research Protocols 14 (2025): e78557.

[302] J. Xu, Z. Liu, J. Shi, and Y. Wang, “How Should China Set Ethical Guardrails for Medical Research?,” Journal of Medical Ethics 50, no. 11 (2024): 744–748.

[303] W. C. Summers, “The Cold War and Phage Therapy: How Geopolitics Stalled Development of Viruses as Antibacterials,” Annual Review of Virology 11, no. 1 (2024): 381–393.

[304] P. D. Tamma, M. Souli, M. Billard, et al., “Safety and Microbiological Activity of Phage Therapy in Persons With Cystic Fibrosis Colonized With Pseudomonas Aeruginosa: Study Protocol for a Phase 1b/2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial,” Trials 23, no. 1 (2022): 1057.

[305] European Medicines Agency. “Ich Q5d Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products—Scientific Guideline.”, https://www.ema.europa.eu/en/ich-q5d-derivation-characterisation-cell-substrates-used-production-biotechnological-biological-products-scientific-guideline.

[306] L. Schaupp, A. Addante, M. Voller, et al., “Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor on Sputum Viscoelastic Properties, Airway Infection and Inflammation in Patients With Cystic Fibrosis,” European Respiratory Journal 62, no. 2 (2023): 2202153.

[307] H. J. Stacey, S. De Soir, and J. D. Jones, “The Safety and Efficacy of Phage Therapy: A Systematic Review of Clinical and Safety Trials,” Antibiotics (Basel) 11, no. 10 (2022): 1340.

[308] M. Fuerst-Wilmes, V. Respondek, M. Schramm, N. Lilienthal, K. Buss, and A. Duechting, “Regulation of Phage Therapy Medicinal Products: Developments, Challenges, and Opportunities,” Frontiers in Cellular and Infection Microbiology 15 (2025): 1631359.

[309] C. Willy and F. Brocker, “[Phage Therapy in Germany-Update 2025],” Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 68, no. 6 (2025): 617–624.

[310] D. Subedi, F. Gordillo Altamirano, R. Deehan, et al., “Rational Design of a Hospital-Specific Phage Cocktail to Treat Enterobacter Cloacae Complex Infections,” Nature Microbiology 10, no. 11 (2025): 2702–2719.

[311] T. Faltus, “The Medicinal Phage-Regulatory Roadmap for Phage Therapy Under Eu Pharmaceutical Legislation,” Viruses 16, no. 3 (2024): 443.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.